Chance Pharmaceuticals has announced a new agreement giving Huadong Medicine the rights to commercialize Chance Pharma’s CXG87 formoterol / budesonide DPI in mainland China. Financial details of the agreement were not disclosed. In March 2025, Chance announced that it had closed a funding round to support Phase 3 development of CXG87. According to the new announcement, a Phase 3 trial of the inhaler for the treatment of asthma has completed enrollment, and Chance says that it expects to submit an NDA by mid-2026.
Huadong Medicine Chairman and General Manager Liang Lv commented, “We see significant potential for CXG87 in respiratory treatment. This partnership will strategically enhance our respiratory pipeline and, by leveraging our nationwide commercial network and specialized promotion team, will enable CXG87 to achieve rapid market access and broad coverage upon launch. We are dedicated to building a strong and synergistic partnership with Chance, harnessing our respective strengths to expedite the launch of this innovative product in China and make its significant clinical benefits available to patients at the earliest opportunity.”
Chance Pharma CEO Donghao Chen said, “As the first product developed on our unique VFC platform, CXG87 is a key differentiated asset that validates the platform’s strong scientific and commercial value. It holds several advantages over the originator product, such as lower flow rate dependency. Our collaboration with Huadong Medicine is a testament to its significant commercial potential and will allow us to leverage their respiratory expertise to maximize its commercial and clinical value. We are committed to working closely together to bring this product to patients suffering from respiratory diseases as quickly as possible.”
Chance Head of R&D Lan Chen added, “Symbicort Turbuhaler is an excellent inhalation therapy. We are proud to have optimized and improved upon it. Through our comprehensive preclinical, Phase 1, and Phase 3 studies, we aim to build a compelling body of evidence to demonstrate its enhanced clinical value. We look forward to making CXG87 a better treatment option for asthma patients with impaired inspiratory flow, ultimately providing a superior treatment choice for the asthma community worldwide.”
Read the Chance Pharmaceuticals press release
